Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Cardiovascular Risk Comparison between Expanded Hemodialysis Using Theranova and Online Hemodiafiltration (CARTOON): A Multicenter Randomized Controlled Trial.
Visit resource site
PD
Case report: Remote monitoring of automated peritoneal dialysis patients: assessing clinical and economic value - Makhija D, et al
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Changes in plasma sclerostin level associated with use of a medium cut-off dialyzer in end-stage renal disease.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Characteristics of protein loss with medium cut-off membranes compared to high flux membranes
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Chronic inflammation in end-stage renal disease and dialysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Citrate anion improves chronic dialysis efficacy, reduces systemic in-flammation and prevents Chemerin-mediated microvascular injury - Dellepiane S et al. Sci Rep 2019
Visit resource site
HD
Citrate versus acetate-based dialysate in on-line haemodiafiltration. A prospective cross-over study - Molina NN, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Classification of Uremic Toxins and Their Role in Kidney Failure: An Expert Consensus Conference
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Clinical Assessment of Dialysis Recovery Timeand Symptom Burden: Impact of Switching Hemodialysis Therapy Mode
Visit resource site
PD
Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study. - le Poole CY, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Clinical Outcomes With Medium Cut-Off Versus High-Flux Hemodialysis Membranes: A Systematic Review and Meta-Analysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Clinical performance comparison of two medium cut-off dialyzers
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.